ROLE OF CD200 IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA

Document Type : Original Article

Authors

1 clinical pathology,department,faculty of medicine,zagazig university

2 clinical pathology department, Faculty of Medicine, Zagazig University

3 medical oncology, department, Faculty of Medicine, Zagazig University

Abstract

Background: Acute myeloid leukemia is a complex and heterogeneous hematopoietic tissue neoplasm caused by gene mutations, chromosomal rearrangements and deregulation of gene expression. Some recent studies considered CD200 as a marker of bad prognosis in AML as it is linked to worse overall survival. The present study aimed to assess CD200 expression frequency in patients with AML and evaluate its association with different clinical and laboratory data.
Subjects & Methods: The study was carried on 28 newly diagnosed AML patients and 10 healthy subjects who served as a control group. All patients were subjected to routine laboratory investigations and measurement of CD200 level by flowcytometry.
Results: The 28 de novo AML patients were 15 males and 13 females with age ranging from 32 to 60 years with a mean±SD 48.32±7.88 years, and 10 healthy subjects who served as a control group with age ranged from 24 to 58 years with a mean ± SD 39.20±12.30 years. Cases were classified into CD200 positive (27 cases) and CD200 negative (1 case). Then Positive CD200 cases were classified into CD200 High expression and CD200 Low; patients with CD200

Keywords

Main Subjects

Zagazig University Medical Journal
Volume 28, Issue 6.1
supplement 1
November 2022
Pages 104-114

Files

Share

How to cite

Statistics